Tsutsui J M, Lario F Cerqueira, Fernandes D R, Kowatsch I, Sbano J C, Franchini Ramires J A, Mathias W
Echocardiography Laboratory, Heart Institute (InCor), University of São Paulo Medical School, Sao Paulo, Brazil.
Heart. 2005 Dec;91(12):1563-7. doi: 10.1136/hrt.2004.054445. Epub 2005 Mar 29.
To determine the safety and cardiac chronotropic responsiveness to early atropine dobutamine stress echocardiography (DSE) in the elderly.
Retrospective study of 258 patients >or= 70 years who underwent early atropine DSE and 290 patients >or= 70 years who underwent conventional DSE. In the early atropine protocol, atropine was started at 20 microg/kg/min of dobutamine if heart rate was < 100 beats/min, up to 2 mg. The cardiac chronotropic responsiveness in the elderly was compared with a control group of patients < 70 years matched for sex, myocardial infarction, diabetes, and treatment with beta blockers and calcium channel blockers.
The dose of dobutamine given to elderly patients was lower during early atropine than during conventional DSE (mean (SD) 29 (7) v 38 (4) microg/kg/min, p = 0.001). Early atropine DSE resulted in diminished incidence of ventricular extrasystoles, non-sustained ventricular tachycardia, bradycardia, and hypotension compared with conventional DSE. In comparison with patients < 70 years, elderly patients required lower doses of dobutamine and atropine and achieved a higher percentage of predicted maximum heart rate (92 (9)% v 88 (10)%, p = 0.0001). Except for more common hypotension (16% v 10%, p = 0.004), no other difference in adverse effects was observed between patients >or= 70 and < 70 years.
Early atropine DSE is a safe strategy in the elderly resulting in lower incidence of minor adverse effects than with the conventional protocol. Elderly patients presented adequate cardiac chronotropic responsiveness to early injections of atropine, requiring lower doses of drugs to reach test end points.
确定早期阿托品多巴酚丁胺负荷超声心动图(DSE)在老年人中的安全性及心脏变时反应性。
对258例年龄≥70岁接受早期阿托品DSE的患者和290例年龄≥70岁接受传统DSE的患者进行回顾性研究。在早期阿托品方案中,如果心率<100次/分钟,则在多巴酚丁胺剂量为20微克/千克/分钟时开始使用阿托品,最大剂量为2毫克。将老年人的心脏变时反应性与一组年龄<70岁、性别、心肌梗死、糖尿病以及β受体阻滞剂和钙通道阻滞剂治疗相匹配的对照组患者进行比较。
早期阿托品治疗期间给予老年患者的多巴酚丁胺剂量低于传统DSE期间(均值(标准差)29(7)微克/千克/分钟对38(4)微克/千克/分钟,p = 0.001)。与传统DSE相比,早期阿托品DSE导致室性早搏、非持续性室性心动过速、心动过缓和低血压的发生率降低。与年龄<70岁的患者相比,老年患者需要较低剂量的多巴酚丁胺和阿托品,并达到预测最大心率的更高百分比(92(9)%对88(10)%,p = 0.0001)。除了更常见的低血压(16%对10%,p = 0.004)外,年龄≥70岁和<70岁的患者在不良反应方面未观察到其他差异。
早期阿托品DSE对老年人是一种安全的策略,与传统方案相比,其轻微不良反应的发生率较低。老年患者对早期注射阿托品表现出足够的心脏变时反应性,达到试验终点所需的药物剂量较低。